Search
Chugai Pharmaceutical Completes Acquisition of Japanese Biopharmaceutical Firm Renalys
2025-10-24 /
Read about 0 minute
Author：小编
On October 24, Chugai Pharmaceutical, a prominent player in Japan's pharmaceutical landscape, declared its intention to acquire Renalys, a local biopharmaceutical enterprise, for a sum of 15 billion yen (roughly equivalent to US$98 million). Renalys is the proud holder of the development and commercialization rights for Sparsentan, a drug specifically designed for kidney treatment, within Japan and across a number of Asian markets. This particular drug has already secured approval in both the United States and Europe. Moreover, it has successfully navigated through its final-stage clinical trials in Japan, with the company now diligently preparing the necessary documentation for submission to regulatory authorities for review.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
